快速分子检测肺炎克雷伯菌碳青霉烯酶及头孢他啶-阿维巴坦使用对碳青霉烯耐药肠杆菌目细菌菌血症结局的影响
该观察性研究纳入2016至2018年纽约和新泽西8家医学中心的137例碳青霉烯耐药肠杆菌目细菌(CRE)菌血症患者,其中89例(65%)产KPC酶。血培养接受blaKPC PCR检测的患者(51例)较未检测者(86例)获得活性治疗时间更短(中位24 vs 50小时,P=0.009),14天死亡率(16% vs 37%,P=0.007)和30天死亡率(24% vs 47%,P=0.007)更低。blaKPC PCR检测与30天死亡率降低相关(调整比值比0.37,95%CI 0.16-0.84)。头孢他啶-阿维巴坦单药治疗30天死亡率为10%,多黏菌素单药治疗为31%(P=0.08)。
要点
- blaKPC PCR检测阳性血培养与CRE菌血症患者获得活性治疗时间缩短及死亡率降低相关。
- 头孢他啶-阿维巴坦单药治疗30天死亡率为10%,多黏菌素单药治疗为31%(P=0.08)。
- 在KPC流行区,blaKPC PCR检测阳性血培养可改善CRE菌血症结局。
核心结论
- 在KPC流行区,对阳性血培养进行blaKPC PCR检测与CRE菌血症患者获得适当治疗时间缩短和死亡率降低相关,头孢他啶-阿维巴坦是这些感染的合理一线治疗。
研究设计与样本
- 观察性研究,纳入2016至2018年纽约和新泽西8家医学中心的137例CRE菌血症患者,评估各中心临床微生物学实践。
主要发现
- 137例患者中89例(65%)产KPC酶。
- 血培养接受blaKPC PCR检测患者(51例)较未检测者(86例)获得活性治疗时间更短(中位24 vs 50小时,P=0.009)。
- blaKPC PCR检测组14天死亡率16% vs 未检测组37%(P=0.007),30天死亡率24% vs 47%(P=0.007)。
- 调整模型中,blaKPC PCR检测与30天死亡率降低相关(调整比值比0.37,95%CI 0.16-0.84)。
- 头孢他啶-阿维巴坦单药治疗30天死亡率为10%,多黏菌素单药治疗为31%(P=0.08)。
关键数值与推荐
- blaKPC PCR检测与30天死亡率降低相关(调整比值比0.37,95%CI 0.16-0.84)。
- 头孢他啶-阿维巴坦单药治疗30天死亡率10%,多黏菌素单药治疗31%(P=0.08)。
临床怎么用
- 在KPC流行区,对阳性血培养进行blaKPC PCR检测可能改善CRE菌血症患者获得适当治疗的时间并降低死亡率。
- 头孢他啶-阿维巴坦是这些感染的合理一线治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with bacteremia due to carbapenem-resistant Enterobacterales (CRE) experience delays until appropriate therapy and high mortality rates. Rapid molecular diagnostics for carbapenemases and new β-lactam/β-lactamase inhibitors may improve outcomes. METHODS: We conducted an observational study of patients with CRE bacteremia from 2016 to 2018 at 8 New York and New Jersey medical centers and assessed center-specific clinical microbiology practices. We compared time to receipt of active antimicrobial therapy and mortality between patients whose positive blood cultures underwent rapid molecular testing for the Klebsiella pneumoniae carbapenemase (KPC) gene (blaKPC) and patients whose cultures did not undergo this test. CRE isolates underwent antimicrobial susceptibility testing by broth microdilution and carbapenemase profiling by whole-genome sequencing. We also assessed outcomes when ceftazidime-avibactam and polymyxins were used as targeted therapies. RESULTS: Of 137 patients with CRE bacteremia, 89 (65%) had a KPC-producing organism. Patients whose blood cultures underwent blaKPC PCR testing (n = 51) had shorter time until receipt of active therapy (median: 24 vs 50 hours; P = .009) compared with other patients (n = 86) and decreased 14-day (16% vs 37%; P = .007) and 30-day (24% vs 47%; P = .007) mortality. blaKPC PCR testing was associated with decreased 30-day mortality (adjusted odds ratio: .37; 95% CI: .16-.84) in an adjusted model. The 30-day mortality rate was 10% with ceftazidime-avibactam monotherapy and 31% with polymyxin monotherapy (P = .08). CONCLUSIONS: In a KPC-endemic area, blaKPC PCR testing of positive blood cultures was associated with decreased time until appropriate therapy and decreased mortality for CRE bacteremia, and ceftazidime-avibactam is a reasonable first-line therapy for these infections.
引用
- Satlin MJ, Chen L, Gomez-Simmonds A, et al. Impact of a Rapid Molecular Test for Klebsiella pneumoniae Carbapenemase and Ceftazidime-Avibactam Use on Outcomes After Bacteremia Caused by Carbapenem-Resistant Enterobacterales. Clin Infect Dis. 2022. PMID: 35522019. doi:10.1093/cid/ciac354
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。